Exclude Patient Type Detail Header
No
Footnote
<sup>1</sup> Moeller KE, et al. Clinical Interpretation of Urine Drug Tests: What Clinicians Need to Know About Urine Drug Screens. <i>Mayo Clin Proc.</i> 2017 May;92(5):774-796. <a href=https://www.mayoclinicproceedings.org/action/showPdf?pii=S0025-6196%2816%2930825-4><u>Free, full-text PDF</u></a>
<br><br>
• Opiate cutoff established by SAMHSA for Federal Workplace Drug Testing Guidelines limits false positives from poppy seed ingestion
<br><br>
<sup>2</sup> Lybalvi. Prescribing information. Alkermes, Inc; 2024.
<br><br>
<sup>3</sup> Rifadin. Prescribing information. sanofi-aventis U.S. LLC; 2023.
<br><br>
<sup>4</sup> Methadose. Prescribing information. Hikma Pharmaceuticals USA Inc; 2023.
<br><br>
<sup>5</sup> Substance Abuse and Mental Health Services Administration. <i>Medications for Opioid Use Disorder.</i> Treatment Improvement Protocol (TIP) Series 63 Publication No. PEP21-02-01-002. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2021. <a href=https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf><u>Free, full-text PDF</u></a>
<br><br>
• Opiate cutoff established by SAMHSA for Federal Workplace Drug Testing Guidelines limits false positives from poppy seed ingestion
<br><br>
<sup>2</sup> Lybalvi. Prescribing information. Alkermes, Inc; 2024.
<br><br>
<sup>3</sup> Rifadin. Prescribing information. sanofi-aventis U.S. LLC; 2023.
<br><br>
<sup>4</sup> Methadose. Prescribing information. Hikma Pharmaceuticals USA Inc; 2023.
<br><br>
<sup>5</sup> Substance Abuse and Mental Health Services Administration. <i>Medications for Opioid Use Disorder.</i> Treatment Improvement Protocol (TIP) Series 63 Publication No. PEP21-02-01-002. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2021. <a href=https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf><u>Free, full-text PDF</u></a>
Detail Type
Text
Detail Text
Patient Type Detail Header (Long)
May cause false-positive result on opiate immunoassay: